Esophagus Adenocarcinoma Clinical Trials

3 recruiting

Esophagus Adenocarcinoma Trials at a Glance

5 actively recruiting trials for esophagus adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Amiens, Amsterdam, and Arras. Lead sponsors running esophagus adenocarcinoma studies include Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Dallas VA Medical Center, and Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest.

Browse esophagus adenocarcinoma trials by phase

Treatments under study

About Esophagus Adenocarcinoma Clinical Trials

Looking for clinical trials for Esophagus Adenocarcinoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Esophagus Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Esophagus Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 15 of 5 trials

Recruiting
Phase 1

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Gastroesophageal Junction AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8+10 more
M.D. Anderson Cancer Center24 enrolled1 locationNCT04615013
Recruiting

"Less-is-more in Barrett-surveillance" Care Evaluation of Barrett's Patients With Low-Risk in Whom Endoscopic Surveillance is Stopped. The BLISS Project.

Barrett EsophagusBarrett Esophagus Adenocarcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)3,156 enrolled1 locationNCT06803147
Recruiting
Phase 2

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Gastroesophageal Junction AdenocarcinomaGastric AdenocarcinomaEsophagus Adenocarcinoma
UNICANCER118 enrolled29 locationsNCT05476796
Recruiting
Phase 2

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Esophagus Adenocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest32 enrolled22 locationsNCT05713838
Recruiting
Phase 2

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Gastroesophageal Junction AdenocarcinomaEsophagus AdenocarcinomaEsophagus Squamous Cell Carcinoma
Dallas VA Medical Center78 enrolled1 locationNCT04018872